1/23
Looks like no tags are added yet.
Coagulation Cascade: FVIII
Activated to FVIIIa by thrombin
Bound to vWF = Activate FX → FXa in intrinsic pathway
Coagulation Cascade: Extrinsic
FVII → FVIIa by TF = TF-FVIIa complex = Activate FX → FXa
Coagulation Cascade: Intrinsic
FXII → FXIIa by neg/damaged surfaces
Exposed collagen, enzymes, proteins
Sequential activation
FXI → FIX → FX
FX → FXa by FVIIIa bound to vWF
Coagulation Cascade: Common
Prothrombin (FII) → Thrombin (FIIa) by FXa and FVa
Thrombin activate:
Fibrinogen (FI) → Fibrin (FIa)
FVIII → FVIIIa
FXIII → FXIIIa
FV → FVa
Fibrin cross-linking by FXIIIa


X-Linked Inheritance: Description
Inheritance through X chromosome from mother and father
Dominant: 1 copy for phenotypical expression
1 from mother OR father
Recessive: 2 copies for phenotypical expression
1 from mother
1 from father
X-Linked Inheritance: Pedigree
Dominant: Women = Men inheritance probability
Recessive: Men > Women inheritance probability
Hemophilia: Description
Hereditary blood clotting disorders
Hemophilia: Epidemiology
Risk factors:
Family history
More common in males
Hemophilia: Etiology
X-linked recessive or antibodies against clotting factors
Hemophilia A: FVIII deficiency (80%)
Hemophilia B: FIX deficiency (20%)
Hemophilia C: FXI deficiency (very rare)
Autosomal recessive
Hemophilia: Pathophysiology
Impair secondary hemostasis intrinsic pathway
A: Decreased FVIII = Decrease FX → FXa cofactor = Decrease clotting
B: Decreased FIX = Decreased FX → FXa precursor = Decrease clotting
C: Decreased FXI = Decreased FIX → FIXa precursor = Decreased FX → FXa = Decrease clotting
Hemophilia: Clinical Presentation
Deep tissue bleeding
Recurrent bruises and hematomas
Hemarthrosis: Joint bleeding
Repeated = Hemophilic arthropathy (joint destruction)
Oral mucosa
Epistaxis
GI
GU
Carriers: Mild symptoms
Hemophilia: Investigations
Genetic testing + prenatal screening
CBC
INR
PT
aPTT
*Mixing study
Basic factor study
Hemophilia: CBC
Normal platelets
Hemophilia: INR
Normal
Hemophilia: PT
Normal
Hemophilia: aPTT
Increased → Mixing study
Hemophilia: Mixing Study
Mix patient plasma + normal plasma
Low patient clotting factors = Normal plasma clotting factors normalize aPTT
Patient clotting inhibitor = Inhibit normal plasma clotting factors = Increased aPTT
Increased aPTT → Basic factor study
Hemophilia: Basic Factor Study
Determine deficient factor
Hemophilia: Treatment/Management
Clotting factor cryoprecipitate transfusion
**Desmopressin
**Emicizumab
Hemophilia Management: Transfusion
Severity:
Mild/Moderate: When needed
Severe: Prophylactic
Prevent excess bleeding and joint bleeds
Replace deficient factor
Consider additional antifibronolytic drugs
Hemophilia Management: Desmopressin
For mild hemophilia A
Increase vWF = Increase FVIII
Hemophilia Management: Emicizumab
Antibody decreasing bleeding events
For hemophilia A
Bind FIXa and FX = FXa = Restore coagulation cascade
Replace FVIII deficiency
Hemophilia: Complications
Blood-borne infections from transfusion
Antibody development against recombinant factors